Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Cygnus Technologies, a subsidiary of Maravai LifeSciences, is the global leader in providing analytical tools and services for the detection and characterization of process-related impurities in biopharmaceutical manufacturing. The company is best known for its 'gold standard' Host Cell Protein (HCP) ELISA kits, which are used by virtually all major pharmaceutical and biotechnology companies to ensure the safety and purity of biologics. Beyond HCP assays, Cygnus offers specialized solutions for viral clearance (MockV), Protein A detection, and advanced orthogonal characterization using its proprietary Antibody Affinity Extraction (AAE) technology. Its products are critical for regulatory compliance and lot release testing throughout the drug development lifecycle, from preclinical stages to commercial manufacturing. Cygnus delivers best-in-class customer service and technical expertise, helping biopharmaceutical companies move new therapeutics more quickly through development and approval stages to market.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Cygnus.